Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

2.

A short history of Lassa fever: the first 10-15 years after discovery.

Monath TP.

Curr Opin Virol. 2019 Jul 16;37:77-83. doi: 10.1016/j.coviro.2019.06.005. [Epub ahead of print] Review.

PMID:
31323506
3.

Bunyavirus Taxonomy: Limitations and Misconceptions Associated with the Current ICTV Criteria Used for Species Demarcation.

Blitvich BJ, Beaty BJ, Blair CD, Brault AC, Dobler G, Drebot MA, Haddow AD, Kramer LD, LaBeaud AD, Monath TP, Mossel EC, Plante K, Powers AM, Tesh RB, Turell MJ, Vasilakis N, Weaver SC.

Am J Trop Med Hyg. 2018 Jul;99(1):11-16. doi: 10.4269/ajtmh.18-0038. Epub 2018 Apr 19.

4.

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia.

Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.

5.

Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species.

Bergren NA, Miller MR, Monath TP, Kading RC.

Hum Vaccin Immunother. 2018 Apr 3;14(4):994-1002. doi: 10.1080/21645515.2017.1412898. Epub 2018 Jan 3.

6.

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton JD, Lane HC; PREVAIL I Study Group.

N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.

7.

Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae.

Smith DB, Meyers G, Bukh J, Gould EA, Monath T, Scott Muerhoff A, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P, Becher P.

J Gen Virol. 2017 Aug;98(8):2106-2112. doi: 10.1099/jgv.0.000873. Epub 2017 Aug 8.

8.

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP.

Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469. doi: 10.1016/j.vaccine.2017.05.097. Epub 2017 Jun 21.

PMID:
28647166
9.

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T, Alimonti J, Rudge TL, Sabourin C, Silvera P, Hooper JW, Kwilas SA, Kilgore N, Badorrek C, Ramsey WJ, Heppner DG, Kemp T, Monath TP, Nowak T, McNeil SA, Langley JM, Halperin SA; Canadian Immunization Research Network.

CMAJ. 2017 Jun 19;189(24):E819-E827. doi: 10.1503/cmaj.170074.

10.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
11.

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia, Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Erratum in: Sci Transl Med. 2019 Aug 21;11(506):.

12.

ICTV Virus Taxonomy Profile: Flaviviridae.

Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff S, Pletnev A, Rico-Hesse R, Smith DB, Stapleton JT, Ictv Report Consortium.

J Gen Virol. 2017 Jan;98(1):2-3. doi: 10.1099/jgv.0.000672.

13.

Responding to the threat of urban yellow fever outbreaks.

Wilder-Smith A, Monath TP.

Lancet Infect Dis. 2017 Mar;17(3):248-250. doi: 10.1016/S1473-3099(16)30588-6. Epub 2016 Dec 23. No abstract available.

14.

Epidemic arboviral diseases: priorities for research and public health.

Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW.

Lancet Infect Dis. 2017 Mar;17(3):e101-e106. doi: 10.1016/S1473-3099(16)30518-7. Epub 2016 Dec 21. Review.

PMID:
28011234
15.

Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens.

Penaloza MacMaster P, Shields JL, Alayo QA, Cabral C, Jimenez J, Mondesir J, Chandrashekar A, Cabral JM, Lim M, Iampietro MJ, Provine NM, Bricault CA, Seaman M, Orlinger K, Aspoeck A, Fuhrmann G, Lilja AE, Monath T, Mangeat B, Pinschewer DD, Barouch DH.

Vaccine. 2017 Jan 3;35(1):1-9. doi: 10.1016/j.vaccine.2016.11.063. Epub 2016 Nov 26.

16.

Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.

Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00300-16. doi: 10.1128/CVI.00300-16. Print 2017 Jan.

17.

Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family.

Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff AS, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P.

J Gen Virol. 2016 Nov;97(11):2894-2907. doi: 10.1099/jgv.0.000612. Epub 2016 Sep 28.

18.

Yellow Fever Remains a Potential Threat to Public Health.

Vasconcelos PF, Monath TP.

Vector Borne Zoonotic Dis. 2016 Aug;16(8):566-7. doi: 10.1089/vbz.2016.2031. Epub 2016 Jul 11.

PMID:
27400066
19.

Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.

Condit RC, Williamson AL, Sheets R, Seligman SJ, Monath TP, Excler JL, Gurwith M, Bok K, Robertson JS, Kim D, Michael Hendry R, Singh V, Mac LM, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2016 Dec 12;34(51):6610-6616. doi: 10.1016/j.vaccine.2016.04.060. Epub 2016 Jun 23. Review.

20.

Yellow fever vaccine supply: a possible solution.

Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL.

Lancet. 2016 Apr 16;387(10028):1599-600. doi: 10.1016/S0140-6736(16)30195-7. Epub 2016 Apr 14. No abstract available. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
27116054
21.

Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI.

Vaccine. 2016 Apr 12;34(17):1993-9. doi: 10.1016/j.vaccine.2016.03.005. Epub 2016 Mar 10.

PMID:
26973071
22.

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Hu Z, Muñoz P, Moon JE, Ruck RC, Bennett JW, Twomey PS, Gutiérrez RL, Remich SA, Hack HR, Wisniewski ML, Josleyn MD, Kwilas SA, Van Deusen N, Mbaya OT, Zhou Y, Stanley DA, Jing W, Smith KS, Shi M, Ledgerwood JE, Graham BS, Sullivan NJ, Jagodzinski LL, Peel SA, Alimonti JB, Hooper JW, Silvera PM, Martin BK, Monath TP, Ramsey WJ, Link CJ, Lane HC, Michael NL, Davey RT Jr, Thomas SJ; rVSVΔG-ZEBOV-GP Study Group.

N Engl J Med. 2017 Jan 26;376(4):330-341. doi: 10.1056/NEJMoa1414216. Epub 2015 Apr 1.

23.

Yellow fever.

Monath TP, Vasconcelos PF.

J Clin Virol. 2015 Mar;64:160-73. doi: 10.1016/j.jcv.2014.08.030. Epub 2014 Oct 24. Review.

PMID:
25453327
24.

Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Monath TP, Seligman SJ, Robertson JS, Guy B, Hayes EB, Condit RC, Excler JL, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2015 Jan 1;33(1):62-72. doi: 10.1016/j.vaccine.2014.10.004. Epub 2014 Oct 27. Review.

25.

In memoriam: Robert Emmons Kissling (1923–2013).

Calisher CH, Murphy FA, Monath TP.

Emerg Infect Dis. 2014 Aug;20(8):1426-7. No abstract available.

26.

A manifesto for planetary health.

Kahn LH, Kaplan B, Monath T, Woodall J, Conti L.

Lancet. 2014 Apr 26;383(9927):1459. doi: 10.1016/S0140-6736(14)60709-1. No abstract available.

PMID:
24766955
27.

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.

Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP.

Viruses. 2013 Dec 9;5(12):3048-70. doi: 10.3390/v5123048. Review.

28.

17D Yellow Fever Virus Vaccine.

Monath TP.

Am J Trop Med Hyg. 2013 Dec;89(6):1225. doi: 10.4269/ajtmh.13-0443a. No abstract available.

29.

Vaccines against diseases transmitted from animals to humans: a one health paradigm.

Monath TP.

Vaccine. 2013 Nov 4;31(46):5321-38. doi: 10.1016/j.vaccine.2013.09.029. Epub 2013 Sep 21. Review.

PMID:
24060567
30.

Adaptation of yellow fever virus 17D to Vero cells is associated with mutations in structural and non-structural protein genes.

Beasley DW, Morin M, Lamb AR, Hayman E, Watts DM, Lee CK, Trent DW, Monath TP.

Virus Res. 2013 Sep;176(1-2):280-4. doi: 10.1016/j.virusres.2013.04.003. Epub 2013 Apr 16.

PMID:
23602827
31.

Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus.

Hanley KA, Monath TP, Weaver SC, Rossi SL, Richman RL, Vasilakis N.

Infect Genet Evol. 2013 Oct;19:292-311. doi: 10.1016/j.meegid.2013.03.008. Epub 2013 Mar 20. Review.

32.

Review of the risks and benefits of yellow fever vaccination including some new analyses.

Monath TP.

Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Review.

PMID:
22551029
33.

Full genomic sequence of the prototype strain (M64) of Rio Bravo virus.

Volkova E, Tesh RB, Monath TP, Vasilakis N.

J Virol. 2012 Apr;86(8):4715. doi: 10.1128/JVI.00331-12.

34.

Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.

Dong L, Liu F, Fairman J, Hong DK, Lewis DB, Monath T, Warner JF, Belser JA, Patel J, Hancock K, Katz JM, Lu X.

Vaccine. 2012 Jan 5;30(2):254-64. doi: 10.1016/j.vaccine.2011.10.103. Epub 2011 Nov 12.

PMID:
22085545
35.

Yellow fever vaccine seroconversion in travelers.

Kay A, Chen LH, Sisti M, Monath TP.

Am J Trop Med Hyg. 2011 Oct;85(4):748-9. doi: 10.4269/ajtmh.2011.11-0363.

36.

The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever.

Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP; Informal WHO Working Group on Geographic Risk for Yellow Fever.

Lancet Infect Dis. 2011 Aug;11(8):622-32. doi: 10.1016/S1473-3099(11)70147-5. Review. Erratum in: Lancet Infect Dis. 2012 Feb;12(2):98.

PMID:
21798462
37.

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Julander JG, Trent DW, Monath TP.

Vaccine. 2011 Aug 11;29(35):6008-16. doi: 10.1016/j.vaccine.2011.06.034. Epub 2011 Jun 28.

38.

An inactivated cell-culture vaccine against yellow fever.

Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW.

N Engl J Med. 2011 Apr 7;364(14):1326-33. doi: 10.1056/NEJMoa1009303.

39.

Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination.

Smith HL, Monath TP, Pazoles P, Rothman AL, Casey DM, Terajima M, Ennis FA, Guirakhoo F, Green S.

J Infect Dis. 2011 Feb 15;203(4):513-22. doi: 10.1093/infdis/jiq074. Epub 2011 Jan 7.

40.

Introduction: one health perspective.

Monath TP, Kahn LH, Kaplan B.

ILAR J. 2010;51(3):193-8. No abstract available.

PMID:
21131719
41.

Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Monath TP.

Am J Trop Med Hyg. 2010 May;82(5):919-21. doi: 10.4269/ajtmh.2010.10-0001.

42.

Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.

Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, Hayman E, Guertin P, Makowiecki J, Crowell J, Levesque P, Bowick GC, Morin M, Fowler E, Trent DW.

Vaccine. 2010 May 14;28(22):3827-40. doi: 10.1016/j.vaccine.2010.03.023. Epub 2010 Mar 26.

PMID:
20347059
43.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
44.

Viscerotropic disease following yellow fever vaccination in Peru.

Whittembury A, Ramirez G, Hernández H, Ropero AM, Waterman S, Ticona M, Brinton M, Uchuya J, Gershman M, Toledo W, Staples E, Campos C, Martínez M, Chang GJ, Cabezas C, Lanciotti R, Zaki S, Montgomery JM, Monath T, Hayes E.

Vaccine. 2009 Oct 9;27(43):5974-81. doi: 10.1016/j.vaccine.2009.07.082. Epub 2009 Aug 11.

PMID:
19679215
45.

'ONE HEALTH' and parasitology.

Kaplan B, Kahn LH, Monath TP, Woodall J.

Parasit Vectors. 2009 Aug 12;2(1):36. doi: 10.1186/1756-3305-2-36. No abstract available.

46.

Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests.

Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, Monath T.

Clin Vaccine Immunol. 2009 Jul;16(7):1052-9. doi: 10.1128/CVI.00095-09. Epub 2009 May 20.

47.

Yellow fever recommendations for tourists to Kenya: a flawed risk assessment.

Monath TP, Gershman M, Hill DR, Marano N, Staples JE, Wilder-Smith A.

J Travel Med. 2009 Mar-Apr;16(2):146; author reply 146-7. doi: 10.1111/j.1708-8305.2008.00295_1.x. No abstract available.

49.

'One health' in action series: nos 1-8.

Kahn LH, Kaplan B, Monath TP.

Vet Ital. 2009 Jan-Mar;45(1):195-208.

50.

The brewing storm.

Kaplan B, Kahn LH, Monath TP.

Vet Ital. 2009 Jan-Mar;45(1):9-18.

Supplemental Content

Loading ...
Support Center